Search PubMed⌕ Search

Biomedical subjects

C Drewes

Publications and source records attributed to C Drewes.

4 recordsLinked to original sources

[Biventricular defibrillation using transvenous electrodes].

This study investigated the feasibility of transvenous biventricular defibrillation using an electrode in a left ventricular vein. The standard lead configuration with a coil in the right ventricle (RV) and a coil in the superior vena cava (SVC) was compared with an additional unipolar coil in an accessible epicardial vein. Only biphasic shocks were used with different shocking modes between the coils in the RV, LV, SVC and the ICD-generator (CAN). Shocks were applied starting with 30 J, decreasing till the DFT was reached. As a result there is a lower DFT when defibrillation is performed including the left ventricular electrode. The impedance did not show a significant increase after more then 20 consecutive shocks. It is a feasible and workable application that might help to reduce the energy demand and increase the safety of such a system.

Animals↗

[Rate-responsive pacemaker concept: parametric system identification].

The focus of this paper is the design of a rate-responsive pacemaker which uses the atrio-ventricular conduction time (AVCT) as an exertion related sensor signal. AVCT can be easily obtained from an intracardial electrogram. During atrial pacing AVCT shortens with exercise but increases with the stimulation rate. Hence, an AVCT based pacemaker always establishes a closed-loop system. General design rules for an AVCT pacemaker have been developed from our experimental results and a system-theoretical treatment. Topics addressed were the controller gain, uncertainties concerning the dynamics of the AVCT, the attenuation of disturbances, the closed-loop bandwidth and stability.

Algorithms↗

A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.

Glucagon-like peptide 1 [7-36 amide] (GLP-1) and the obese gene product (leptin) are thought to be involved in the central regulation of feeding. Both may act from the peripheral circulation to influence brain function. To study potential interactions, GLP-1 ([7-36 amide]: 0.4, 0.8 pmol kg-1 min-1 or placebo on separate occasions) was infused intravenously (from -30 to 240 min) into nine healthy volunteers [age 26 +/- 3 years, body mass index: 22.9 +/- 1.6 kg/m2, glycated haemoglobin HbA1c: 5.0% +/- 0.2% (normal: 4.0%-6.2%), creatinine: 1.1 +/- 0.1 mg/dl], and (at 0 min) a liquid test meal (50 g sucrose in 400 ml 8% amino acid, total amino acids 80 g/l) was administered via a nasogastric tube. Plasma leptin (radioimmunoassay, RIA), glucose, insulin (microparticle enzyme immunoassay), C-peptide (enzyme-linked immunosorbent assay) and GLP-1 (RIA) were measured, and statistical analysis was done with repeated-measures ANOVA and Student's t-test. Plasma leptin concentrations were 31 +/- 6 pmol/l in the basal state. They did not change within 240 min after meal ingestion nor in response to the infusion of exogenous GLP-1 [7-36 amide] (P = 0.99 for the interaction of experiment and time) leading to GLP-1 mean plasma levels of 25 +/- 2 and 36 +/- 3 (basal 6 +/- 1) pmol/l. On the other hand, glucose (from basal 4.7 +/- 0.1 to 6.0 +/- 0.2 mmol/l at 15 min, P < 0.05) and insulin (from basal 28 +/- 2 to 325 +/- 78 pmol/l at 45 min, P < 0.05) increased clearly after the meal with placebo. In conclusion, (1) plasma leptin levels in normal human subjects show no short-term changes after feeding a liquid mixed meal and (2) do not appear to be directly influenced by physiological and pharmacological elevations in plasma GLP-1 [7-36 amide] concentrations. This does not exclude interactions at the cerebral (hypothalamic) level or on more long-term temporal scales.

Adult↗

Elevated plasma levels of transforming growth factor-beta 1 in NIDDM.

OBJECTIVE: Transforming growth factor-beta (TGF-beta) is a potent inducer of extracellular matrix production and of fibrogenesis and has been associated with the occurrence of diabetic micro- and macrovascular complications. Our aim was to determine whether circulating levels of TGF-beta 1 are altered in NIDDM and, if so, whether they are correlated with blood glucose and show an association with diabetic complications. RESEARCH DESIGN AND METHODS: Plasma levels of TGF-beta 1 were determined by enzyme-linked immunosorbent assay in 44 NIDDM patients and 28 control subjects of comparable age and weight and were correlated with parameters of metabolic control and the occurrence of micro- and macrovascular complications. RESULTS: TGF-beta 1 was significantly elevated in NIDDM (7.9 +/- 1.0 ng/ml), as compared with control subjects (3.1 +/- 0.4 ng/ml, P < 0.001) and correlated with glycosylated hemoglobin (r2 = 0.42; P < 0.001). Thrombocyte levels of TGF-beta 1 were similar in control subjects (54 +/- 7 pg/ml, n = 16) and diabetic patients (61.6 +/- 18 pg/ml, n = 13; P = 0.357). Elevated TGF-beta 1 levels were associated with retinopathy and neuropathy. CONCLUSIONS: We conclude that plasma levels of TGF-beta 1 are elevated in NIDDM patients and may be related to average blood glucose. Preliminary data suggest that they may contribute to the occurrence of diabetic complications.

Aged↗